TG Therapeutics to Participate in the Cantor Global Healthcare Conference
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
TGTX - TG Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$80.50
DETAILS
HIGH:
$83.00
LOW:
$78.00
MEDIAN:
$80.50
CONSENSUS:
$80.50
UPSIDE:
44.42%
Stock News
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG
Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 235,481 shares of the biopharmaceutical company's stock, valued at approximately $12,937,000. Deutsche Bank AG owned 0.15%
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.
Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX
Bank of America Corp DE lifted its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 71.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,461,302 shares of the biopharmaceutical company's stock after buying an additional 610,195 shares
Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX
Assenagon Asset Management S.A. decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 82.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,681 shares of the biopharmaceutical company's stock after selling 418,373 shares during the period. Assenagon Asset
Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $63.00
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average rating of "Hold" from the nine brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi
Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX
Empowered Funds LLC lifted its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 49.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,429 shares of the biopharmaceutical company's stock after acquiring an additional 28,452 shares during the quarter.
TG Therapeutics: Why I'm Staying Long After The Q2 Selloff
TG Therapeutics, Inc. remains a Buy as BRIUMVI's momentum supports a durable, growing multiple sclerosis franchise. TGTX's Q2 saw BRIUMVI revenue surge 64% YoY to $228 million, prompting 2026 guidance to $950 million, though net income was impacted by manufacturing investments. Subcutaneous BRIUMVI, with Phase 3 data expected late 2026 or early 2027, could expand the addressable market and drive future gross margin tailwinds.
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.
TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings
The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TG Therapeutics Q2 Earnings Call Highlights
TG Therapeutics NASDAQ: TGTX reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment persistence.
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.17 per share a year ago.
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S. net product revenue target to approximately $890 - 905 million Conference call to be held today, Monday, August 3, 2026, at 8:30 AM ET NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S.
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S.
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Price Targets
TG Therapeutics (TGTX) PT Raised to $78 at H.C. Wainwright
$78.00
(was $46.17)
Emily Bodnar
·
H.C. Wainwright
TG Therapeutics price target raised to $83 from $57 at Jefferies
$83.00
(was $54.40)
Jefferies
TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright
$70.00
(was $39.75)
H.C. Wainwright
TG Therapeutics price target raised to $39 from $37 at Goldman Sachs
$39.00
(was $29.54)
Goldman Sachs
TG Therapeutics assumed with a Buy at H.C. Wainwright
$60.00
(was $36.70)
Emily Bodnar
·
H.C. Wainwright
TG Therapeutics (TGTX) PT Raised to $55 at H.C. Wainwright
$55.00
(was $12.93)
Edward White
·
H.C. Wainwright
TG Therapeutics price target raised to $20 from $18 at Goldman Sachs
$20.00
(was $20.58)
Corinne Jenkins
·
Goldman Sachs
TG Therapeutics (TGTX) PT Raised to $49 at H.C. Wainwright
$49.00
(was $8.21)
Edward White
·
H.C. Wainwright
Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to $24
$24.00
(was $18.48)
Cantor Fitzgerald
Evercore ISI Group Maintains Outperform on TG Therapeutics, Raises Price Target to $16
$16.00
(was $11.83)
Evercore ISI
TG Therapeutics price target raised to $24 from $19 at H.C. Wainwright
$24.00
(was $4.23)
Edward White
·
H.C. Wainwright
Goldman Sachs Maintains Sell on TG Therapeutics, Lowers Price Target to $5
$5.00
(was $7.26)
Goldman Sachs
Has TG Therapeutics Stock Hit Bottom? Looking for the Silver Lining
$23.00
(was $3.46)
Mayank Mamtani
·
Telsey Advisory